Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

PathAI Announces Research Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting

PathAI

PathAI, a leading technology company which combines AI-powered pathology solutions and algorithm deployment expertise with end-to-end central pathology and histology services, today announced it will present research on advances in AI-based approaches through four poster presentations at the American Association for the Study of Liver Diseases Conference on November 10-14 in Boston, Massachusetts. The posters showcase PathAI’s ongoing commitment to cutting-edge research that advances the understanding and treatment of NASH/MASH using AI-powered digital pathology. Machine learning-assisted fibrosis staging in H&E-stained tissue is comparable to staging with Masson’s Trichrome in non-alcoholic steatohepatitis (poster 2070-A) In this research, PathAI demonstrated the utility of its novel, proprietary AI-powered digital pathology product called NASH Explor e TM to detect collagen and fibrosis signals from H&E-stained whole slide images, and enable liver pathologists to accurately stage fibrosis from these H&E images. Furthermore, the co-authors demonstrated that leveraging the AI-derived fibrosis heatmap overlays over H&E whole slide images for fibrosis staging reduced inter-pathologist staging variability relative to staging performed via Masson’s Trichrome. These results motivate further investigation into the potential to reduce the need for Masson’s Trichrome staining in NASH/MASH clinical trial workflows. This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T. AI-based cellular-level characterization of tissue microarchitecture in non-alcoholic steatohepatitis (poster 2006-A) NASH Explore TM is an AI-powered digital pathology tool that enables automated detection, visualization, and zonated quantification of 14 categories of tissue regions and over 10 cell types, producing a panel of >1000 quantitative Human-Interpretable histologic Features (HIFs) from H&E whole slide images of liver biopsy tissue. In this collaborative research project, the co-authors demonstrate the biological validity of the quantitative histologic features generated by NASH Explore TM. This work will be presented on Saturday, November 11 from 1:00-2:00 p.m. E.T. Artificial intelligence-based measurement of non-alcoholic steatohepatitis (AIM-NASH) improves individual pathologists accuracy and decreases inter-pathologist variability in NASH assessment (poster 2010-A) In this study, Artificial Intelligence-based Measurement of Non-Alcoholic Steatohepatitis (AIM-NASH) algorithm was evaluated for accuracy alone and for use as an assistive tool to pathologists in assessment of liver biopsies in a NASH clinical trial population. This research demonstrates that AIM-NASH may help to standardize histologic scoring for NASH by increasing accuracy for lobular inflammation and ballooning, the features most difficult to score in clinical trial populations. Use of AI-assist AIM-NASH also increased agreement between pathologists for all features. This work will be presented on Saturday, November 11 from 8:00-9:00 a.m. E.T. Artificial intelligence-based measurement of NASH Histology (AIM-NASH) recapitulates primary results from Phase 3 study of resmetirom for treatment of NASH/MASH (Abstract #48735) AIM-NASH TM is an AI-powered digital pathology tool that accurately and reproducibly performs NASH CRN scoring of steatosis, ballooning, lobular inflammation, and fibrosis from whole slide images of H&E- and Masson’s Trichrome-stained liver biopsy tissue. In this collaborative research project, the co-authors demonstrate that all primary histologic endpoints that were met by the central pathologists in a Phase 3 study of resmetirom for treatment of NASH/MASH were also met with statistical significance by AIM-NASH, with clear detection of a dose-response. This adds to the existing body of evidence suggesting that AIM-NASH TM detects true drug effect, while also offering highly repeatable and reproducible histologic scoring. This work will be presented on Monday, November 13 from 1:00-2:00 p.m. E.T. Please visit the PathAI booth, D3100, to learn more and meet the team. About PathAI PathAI is a recognized leader in the biopharma partnering space, uniquely combining AI-powered pathology solutions with end-to-end central pathology and histology services. The company supports biopharma partners in executing clinical trials where pathology-based endpoints, biomarker classification, and/or superior histology quality are critical to successfully gauging therapeutic efficacy, accelerating drug development for complex diseases. PathAI has already supported multiple Phase 2 clinical trials in NASH, IBD, and breast cancer, as well as oncology neoadjuvant trials, and is now expanding into larger scale global Phase 3 studies, as well as additional indications. PathAI provides a fully integrated approach to clinical trials, enabling pharma partners to leverage the power of AI without the heavy lift of implementation. This helps reduce the impact of challenges associated with clinical trials, including unreliable turnaround times, variable histology, stain or scan/digitization quality, and challenging assessment of histological endpoints. The lab offers all major immunohistochemistry staining platforms, with flexible workflows across different scanners, stains, and biopsy types, which improves the quality of clinical trials. Services include access to PathAI’s extensive network of over 500 US Board Certified pathologists to perform high quality reading with rapid turnaround time in a cost-effective manner, plus seamless integration of PathAI's advanced AI-solutions to ensure high-quality, reproducible results with every scan. PathAI is headquartered in Boston, MA, and manages a CAP/CLIA-certified diagnostics clinical laboratory (formerly known as Poplar Healthcare) – one of the country’s largest anatomic pathology labs – in Memphis, TN. For more information, please visit www.pathai.com Contact Details SVM Public Relations and Marketing Communications +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

November 10, 2023 10:00 AM Eastern Standard Time

NuggMD is providing FREE Medical Cannabis Evaluations to Veterans on Veterans Day

NuggMD

NuggMD, the nation's leading telemedicine platform, is providing free online medical marijuana evaluations to veterans on November 10th and 11th, 2023. "We owe our prosperity and freedom to our brave veterans," said Alex Milligan, Chief Marketing Officer and Co-Founder of NuggMD. "These completely free evaluations are our small way of offering humble thanks and gratitude for their service and sacrifices." "Rates of PTSD range from 10% to 30% among war-time veterans," said Collin Mann, NuggMD CEO and Co-Founder. "9.1% suffer from chronic pain. These veterans need options. The solutions aren't one-size-fits-all. Of those who use cannabis, more than 40% report using it for medical reasons, and these patients deserve to have this option. This is their right, but money's tough right now. So we're here to help." NuggMD is making it simple for veterans to use this benefit on Veterans Day. Simply click the live chat feature on the website to speak to a NuggMD support representative. The next available customer service agent will walk the applicant through the process of supplying their proof of service. NuggMD's affiliated medical cannabis practitioners have provided close to 2 million evaluations since their launch in 2016. The free evaluations will be offered to all veterans seeking a medical marijuana evaluation in California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia who provide valid proof of service and their state-issued identification. Veterans can access this benefit for the entire business day on 10/10/23 and 10/11/23, from 8 AM to 10 PM in their local time zone. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

November 09, 2023 12:02 PM Eastern Standard Time

How Over-The-Counter Medicines Could Impact Your Blood Pressure

YourUpdateTV

Would it surprise you to know that nearly half of all adults in the country have elevated blood pressure, and most don’t even know it? Yet only 30% have spoken with a healthcare professional about the adverse effects some over-the-counter medicines can have on their blood pressure. Recently, Dr. Mitch Elkind, American Heart Association’s Chief Clinical Science Officer, conducted a satellite media tour to share precautionary measures that people with high blood pressure need to take before using over-the-counter medications, especially if they have pre-existing conditions or are on other medications. A video accompanying this announcement is available at: https://youtu.be/x7bVSA55fJ0 High blood pressure, (also referred to as hypertension) is when your blood pressure, the force of blood flowing through your blood vessels, is consistently too high. The best way to know if you have high blood pressure it is to have your blood pressure checked. How to use a home blood pressure monitor Be still. Discuss how to use your home blood pressure monitor with your health care professional. Don't smoke, drink caffeinated beverages or exercise within 30 minutes before measuring your blood pressure. Empty your bladder and ensure at least five minutes of quiet rest before measurements. Sit correctly. Sit with your back straight and supported (on a dining chair, rather than a sofa). Your feet should be flat on the floor and your legs should not be crossed. Your arm should be supported on a flat surface, such as a table, with the upper arm at heart level. Make sure the bottom of the cuff is placed directly above the bend of the elbow. Check your monitor's instructions for an illustration or have your health care professional show you how. Measure at the same time every day. It’s important to take the readings at the same time each day, such as morning and evening. It is best to take the readings daily, ideally beginning two weeks after a change in treatment and during the week before your next appointment. Take multiple readings and record the results. Each time you measure, take two readings one minute apart and record the results using a printable (PDF) tracker. If your monitor has built-in memory to store your readings, take it with you to your appointments. Some monitors may also allow you to upload your readings to a secure website after you register your profile. Don't take the measurement over clothes. If you get a high blood pressure reading If your blood pressure is higher than 180/120 mm Hg and you are experiencing signs of possible organ damage such as chest pain, shortness of breath, back pain, numbness/weakness, change in vision or difficulty speaking, do not wait to see whether your pressure comes down on its own. Call 911, as this is an emergency. A single high reading is not an immediate cause for alarm. If you get a reading that is slightly or moderately higher than normal, take your blood pressure a second time and write the results of the two measurements down. Consult your health care professional to verify if there’s a health concern or whether there may be any issues with your monitor. If your blood pressure readings suddenly exceed 180/120 mm Hg, wait five minutes and test again. If your readings are still unusually high, contact your health care professional immediately. You could be experiencing a hypertensive crisis. AHA recommendation The American Heart Association recommends home monitoring for all people with high blood pressure to help the health care professional determine whether treatments are working. Home monitoring, or self-measured blood pressure, is not a substitute for regular visits to your physician. If you have been prescribed medication to lower your blood pressure, don't stop taking your medication without consulting your health care professional, even if your blood pressure readings are in the normal range during home monitoring. Understanding Over-the-Counter (OTC) Medications and High Blood Pressure Look for warnings related to high blood pressure medication. Always read the labels on all over-the-counter medications, especially if you have high blood pressure, also known as hypertension. Look for warnings to those with high blood pressure and to those who take blood pressure medications. If you have high blood pressure and certainly if you are on prescription medication, consult your health care professional before taking any over-the-counter medications or supplements. Be careful with supplements or natural (naturopathic) remedies. There are no special pills, vitamins or drinks that can substitute for prescription medications and lifestyle modifications. Talk to your health care professional before taking any over-the-counter drug or supplement that claims to lower your blood pressure. They may not work as advertised and/or may interfere with other medications. In fact, some can even raise your blood pressure. Decongestants may raise your blood pressure. People with high blood pressure should be aware that the use of decongestants may raise blood pressure or interfere with the effectiveness of some prescribed blood pressure medications. Be aware of over-the-counter cold and flu preparations that contain decongestants as well. Discuss any medications you wish to use with your health care professional. Check the sodium content. Some over-the-counter medications are high in sodium, which can also raise blood pressure. Look at the active and inactive ingredients lists for words like “sodium” or “soda.” Note the amount of sodium in the medication. People with high blood pressure should consume less than 1,500 mg of sodium per day from all sources — one dose of some over-the-counter medications can contain more than a whole day’s allowance. Other drugs and substances that can raise your blood pressure include: Alcohol Amphetamines Antidepressants Atypical antipsychotics (for example, clozapine and olanzapine) Caffeine Cocaine Oral contraceptives Non-steroidal anti-inflammatory drugs, or NSAIDs (for example, ibuprofen and naproxen sodium) Systemic corticosteroids (for example, prednisone and methylprednisolone) Do not stop taking any prescribed medications without discussing with your health care professional. To learn more visit: heart.org/bptools About Talent Mitchell S. V. Elkind, MD, MS, FAAN, FAHA is a tenured Professor of Neurology and Epidemiology at Columbia University, and the Chief Clinical Science Officer at the American Heart Association as of September 2022. He received his medical degree from Harvard Medical School, and he trained in Internal Medicine at Brigham and Women’s Hospital and in Neurology at Massachusetts General Hospital, both in Boston, MA. He completed a fellowship in Vascular Neurology and Neuroepidemiology at Columbia University Medical Center. Dr. Elkind holds a Master’s degree in Epidemiology from Columbia’s Mailman School of Public Health. Dr. Elkind’s research focuses on stroke prevention, inflammatory and infectious biomarkers in stroke risk prediction, atrial cardiopathy, immune therapy for acute stroke, and vascular causes of cognitive aging. He is the second neurologist to serve as President of the American Heart Association (AHA) in its 100 year history, from 2020-2021. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X, or by calling 1-800-AHA-USA1. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 09, 2023 10:57 AM Eastern Standard Time

Video

AmeriLife Gives Back Foundation Names Honor Flight Network as Inaugural Partner

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that its philanthropic arm, the AmeriLife Gives Back Foundation, has chosen the Honor Flight Network as its inaugural, national partner. Founded in 2022, the AmeriLife Gives Back Foundation honors the company’s legacy of giving while helping to connect its growing business, philanthropic and volunteer endeavors. The foundation – through donations of time, money and other resources – focuses on causes that enable the senior community in furtherance of AmeriLife’s commitment to helping people live longer, healthier lives. “As a values-driven company, giving back is in AmeriLife’s DNA and has been an important part of who we are for more than 50 years,” said Scott R. Perry, chairman and CEO of AmeriLife. “I’m incredibly excited that we’re joining forces with the Honor Flight Network, and I can’t wait to see what the future holds for our partnership.” The Honor Flight Network is a national nonprofit that honors America’s military veterans – especially those who served during World War II, the Korean War and the Vietnam War – by bringing them, free of charge, to Washington, D.C. to visit the memorials that commemorate their sacrifice and service. Since 2005, Honor Flight Network has transported more than 300,000 veterans from all 50 states and Puerto Rico to our nation’s capital, and continues to expand its network of more than 125 hubs across the country in an effort to serve even more veterans and their families. In doing so, the Honor Flight Network and its partners deliver gratitude and appreciation for veterans’ contributions to our freedoms, offering them an opportunity to meet other veterans, remember the fallen, and share their stories and experiences. “Honor Flight Network is tremendously grateful for the generous support from AmeriLife,” said Meredith Rosenbeck, CEO of Honor Flight Network. “We are fortunate to call them a valued partner, recognizing and validating our important mission to honor America’s heroes. In joining forces with Honor Flight, AmeriLife is setting the standard of giving with gratitude, and we look forward to a rewarding partnership ahead.” “We’re privileged to be counted among Honor Flight Network’s partners and look forward to a long and rewarding relationship,” added Jim Quinn, Chief Financial Officer for AmeriLife. “Today’s donation opens up exciting opportunities for AmeriLife’s employees and partners to volunteer in support of future Honor Flight Network trips, helping to create memorable experiences for so many of our nation’s heroes.” For more information on the Honor Flight Network and to support its mission directly, donate or volunteer today at HonorFlight.org. To learn more about the AmeriLife Gives Back Foundation, visit us online at AmeriLife.com/GivesBack. ### About Honor Flight Network The Honor Flight Network was formed in 2005 with a mission of honoring our nation’s veterans by bringing them to Washington, DC to visit the memorials and monuments dedicated to their service and sacrifice. The Honor Flight Network is currently comprised of over 130 hubs throughout the country dedicated to carrying out the Honor Flight mission. In addition to World War II veterans, the organization transports those who served in the Korean War, Vietnam War, intermediary operations, and in special cases of terminal illness or injury, veterans from more recent service eras. Since 2005, the Honor Flight Network has taken more than 250,000 veterans to Washington D.C. For more information, visit honorflight.org. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as a leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details AmeriLife Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Honor Flight Network Marion Watkins +1 202-302-4937 mwatkins@honorflight.org Company Website https://amerilife.com/

November 09, 2023 10:00 AM Eastern Standard Time

Cigar Association Urges OMB to Reject FDA's Proposed Flavored Cigar Ban

Cigar Association of America

The Cigar Association of America (CAA) said that it asked the Office of Management and Budget (OMB) during a November 6 meeting to withdraw the Food and Drug Administration (FDA) Flavored Cigar Product Standard (FCPS) banning flavors in cigars, which it said would cost the industry nearly $4 billion in sales—up to 47 percent of industry sales—and destroy 16,000 jobs. CAA president David Ozgo stated, “We presented evidence to OMB that FDA’s proposed flavored cigar ban dramatically fails to meet the criteria necessary for such a ban under the Tobacco Control Act, offering little or no public health benefit while having a devastating economic impact on the industry.” Ozgo noted, “FDA claims the product standard will reduce youth usage of cigars and that prohibiting flavored cigars will address health disparities in minority adult subpopulations. CAA showed OMB government data demonstrating that neither of these claims is true.” FDA Ignores Science on Health Effects & Clear Economic Impact In order for FDA to impose a flavored cigar ban through a FCPS, the law requires that the Agency consider: whether the potential product standard is appropriate for the public health, taking into consideration scientific evidence concerning the risks and benefits to the population as a whole; the increased or decreased likelihood that existing users of tobacco products will stop using such products; and, the increased or decreased likelihood that those who do not use tobacco products will start using such products. “FDA’s Flavored Cigar Product Standard fails on all three accounts,” Ozgo charged, “Youth usage rates of cigars, and of flavored cigars in particular, are at all-time lows and these low rates reflect a stable and sustained trend.” The 2022 National Youth Tobacco Survey (“NYTS”) showed past 30‐day youth cigar use at 1.85% and past 30‐day youth flavored cigar use at 0.83%. The recently released 2023 NYTS data showed past 30‐day youth cigar use has declined to 1.6%. While the flavored cigar use data has not yet been released, it is expected to follow the trend at under 1% of use. Other government surveys reflect similar trends. In fact, the most recent Population Assessment of Tobacco and Health Survey (PATH) showed that past 30-day youth usage of cigars was only 0.70% and past 30-day youth usage of flavored cigars was just 0.14%. In addition to unsupported youth usage claims, CAA demonstrated FDA failed to show that adult subpopulation health disparities are associated with flavored cigar use or that banning flavored cigars would remedy these disparities among Black, Non-Hispanic Americans. CAA did so despite the fact that FDA is required by law to base its decisions not on subpopulation impacts but on impacts to the population as a whole. 1 (See note 1) “FDA’s claims aside, there is simply not a pattern of use of these products that raises a concern of public health that can justify eliminating an entire category of products, while depriving adult consumers of the right to choose these products” he said. While the public health case is non-existent, FDA’s proposal would have dramatically negative economic consequences. A recent study by the Policy Navigation Group showed the flavored cigar ban would reduce retail sales by nearly $4 billion, up to 47 percent of industry sales, causing some 16,000 people to lose their jobs. FDA Recently Lost in Court After Ignoring Scientific Evidence CAA and other industry groups recently convinced a court to reject the Agency’s effort to regulate “premium” cigars. More particularly, the judge in the case ruled against the FDA, citing the Agency for ignoring the scientific evidence. The proposed FCPS similarly ignores scientific evidence. Ozgo stated, “Just as it did in 2016 and 2019, we urge OMB to again reject FDA’s flavored cigar proposal. There is little or no public health benefit from the proposed FCPS, but huge negative economic consequences will result. This is as bad as public policy gets. Ultimately, FDA’s proposal is a solution in search of a problem.” CAA is a national trade association representing manufacturers, distributors, importers, suppliers, and all channels of retailers in the cigar industry, and traces its roots back to the 1890s. 1 The most recent PATH data (Wave 6), collected in 2021, reports that, in the overall adult population, Black, Non‐Hispanic use of flavored cigars had fallen to 1.86% from 3.22% in Wave 5 (collected in 2019). Further, in the young adult population (18–25‐year‐olds) the past 30‐day prevalence rate had fallen to 0.76% in Wave 6 from 1.57% in Wave 5. Contact Details Frank Coleman +1 202-223-8204 fcoleman@cigarassociation.com

November 08, 2023 12:30 PM Eastern Standard Time

Hydrogen Utopia International confident in demand surge for medical cannabis

Hydrogen Utopia International PLC

Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) CEO Aleksandra Binkowska and Howard White, Executive Director of the same company and 100% owner of Ohrid Organics speak to Proactive's Thomas Warner about HUI's recent step into the medical cannabis sector through an investment in North Macedonia-focused grower Ohrid Organics. Binkowska explains that her passion for establishing a waste plastic-to-hydrogen facility is behind the decision to partner with Ohrid Organics, emphasising the importance of HUI becoming financially self-sufficient. The shift in strategy is the result of slower than expected progress in garnering governmental grants and a reluctance to ask the market for fresh funding. Howard White shares his journey as an established investor in waste-to-energy and gives an overview of developments at Ohrid Organics' King Field facility. He expresses confidence in the future of the site and says that he sees the liberalisation of medical cannabis legislation, particularly in conflict-afflicted areas as a potentially lucrative opportunity. Ohrid Organics highlights on its website that North Macedonia has the lowest cost per gram for cannabis production in Europe. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 08, 2023 09:11 AM Eastern Standard Time

Video

HKBU-led research discovers therapeutic potential of hyodeoxycholic acid for non-alcoholic fatty liver disease

Hong Kong Baptist University

HONG KONG SAR - Media OutReach - 8 November 2023 - A research led by Hong Kong Baptist University (HKBU) has discovered that hyodeoxycholic acid (HDCA), a bile acid generated in human intestine, can reduce fat accumulation and inflammation in the liver, demonstrating its strong therapeutic potential for non-alcoholic fatty liver disease (NAFLD). The research also found that HDCA's intervention in NAFLD works by reshaping the population of beneficial gut bacteria, which affects the metabolic interactions between the gut and the liver. The result highlighted the critical role of gut health in liver disease. The research findings have been published in the renowned scientific journal Cell Metabolism. HKBU researchers will coordinate a phase I and II clinical trial in the Mainland to evaluate the safety and efficacy of HDCA for patients with fatty liver disease and type 2 diabetes. 32% of adults suffer from NAFLD NAFLD is a leading cause of chronic liver disease, characterised by the build-up of excessive fat in liver cells that is not caused by alcohol consumption. Its global prevalence has been increasing over time. A meta-analysis in 2022 estimated that 32% of the adult population is affected by NAFLD. Some people with NAFLD can develop non-alcoholic steatohepatitis, which is marked by liver inflammation and may progress to cirrhosis and liver failure. Currently, there are no therapeutic drugs available for sale on the market for non-alcoholic steatohepatitis. A research led by Professor Jia Wei, Acting Dean and Chair Professor in Chinese Medicine and Systems Biology of the School of Chinese Medicine at HKBU, discovered that HDCA offers promising potential as a pharmaceutical intervention for NAFLD. "Our research is a significant stride forward in understanding the pathophysiology of NAFLD, and it offers a potential new avenue for therapeutic intervention," he said. Therapeutic effects of HDCA Professor Jia's team found that individuals with NAFLD have lower levels of HDCA compared to those without NAFLD. In a cohort consisting of 178 patients with NAFLD and 73 healthy individuals, hyocholic acid species, including HDCA and its major metabolite glycohyodeoxycholic acid, comprises 0.5% of the bile acids in NAFLD patients, which is significantly lower than the 2% in healthy individuals. This observation led the team to explore HDCA's potential therapeutic role. A series of controlled experiments were conducted to evaluate the therapeutic effect of HDCA. The team orally fed HDCA to mouse models with NAFLD for eight weeks. The results showed that HDCA markedly reduced excessive lipid droplets, and improved hepatic inflammation, oral glucose tolerance (i.e. the blood glucose level after oral intake of glucose), and insulin sensitivity (i.e. the sensitivity of the body to the effects of insulin which helps the glucose to enter into the cells for use) compared to the control group. The results revealed that HDCA alleviated NAFLD conditions and the risk factors of NAFLD such as type 2 diabetes and insulin resistance. Interestingly, the researchers found that HDCA did not exert its therapeutic effects on NAFLD by directly targeting liver cells. They evaluated the potential direct effect of HDCA on lipid accumulation in a mouse model. The results showed that lipid accumulation was barely affected by the HDCA. They hypothesised that HDCA induced gut microbiota alterations, which might contribute to the alleviation of NAFLD. HDCA reshapes gut microbiota The researchers observed that HDCA could improve the population of beneficial gut bacteria. Parabacteroides distasonis (P. distasonis), a member of the core microbiome in the human gut, sharply increased in the mouse model fed with high-fat food and administered with HDCA, compared with the control group fed with high-fat food only. The results revealed that HDCA provided a favorable environment for the thriving of P. distasonis, which regulates fatty acid metabolism as well as the hepatic bile acid synthesis pathways. "The study underscores the crucial role of the gut-liver metabolic axis in disease management. We hope that the research findings on HDCA and the clinical trial to be conducted in the Mainland will provide more insights into the treatment of fatty liver disease and non-alcoholic steatohepatitis," said Professor Jia. Professor Jia has also led a research project investigating the molecular connections between metabolic-associated fatty liver disease and type 2 diabetes mellitus, with a specific focus on host-gut microbiota interactions. The project has been awarded over HK$7.2 million in research funding from the Theme-based Research Scheme (13th round) under the Research Grants Council. Contact Details Christina Wu christinawu@hkbu.edu.hk

November 08, 2023 09:00 AM Eastern Standard Time

Image

News Release

NuggMD Launches Its Leading Marijuana Telemedicine Service in Florida

NuggMD

NuggMD, the nation's largest medical marijuana telemedicine platform, has launched its industry-leading service in Florida, with an initial focus on the metro areas of Miami, Tampa, Orlando, and Fort Myers. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians in 27 states. Florida's medical cannabis law requires an in-person examination for the initial patient assessment, but the biannual follow-up evaluations can now be conducted via telehealth due to a recent change in the law. “We are thrilled to bring our life-changing telehealth services to Florida. The state’s 210-day renewal mandate poses real barriers for the state's medical cannabis patients. While we hope their legislature will do more to ease access in the near future, especially in light of likely cannabis rescheduling, we're happy that lawmakers chose to ease that burden by making telehealth a permanent option for renewal,” said Alex Milligan, NuggMD co-founder and CMO. "Our initial focus is in these four metro areas because that's where we saw the most demand," said Kam Babazade, NuggMD co-founder and COO. "We've already received a surprisingly robust response, and are planning to expand this new hybrid service to several more states in the near future. Meanwhile, we look forward to expanding our service to the rest of Florida in the coming weeks to help ease the increased regulatory burdens these patients face.” "We've helped to divert over a million medical cannabis patients from the black market now," said Collin Mann, NuggMD co-founder and CEO. "States must ease access to legal cannabis and reduce patient costs if they want to keep these patients away from dangerous black market products. This was a wise move on Florida's part, and we're doing our part too. With the addition of Florida, over 240 million Americans now have access to our platform where they can receive candid guidance from knowledgeable, fully licensed practitioners." It costs just $179 for the initial in-person evaluation and an additional $159 for follow-up telehealth appointments at seven months. Medical cannabis certifications must be renewed with the state every year. NuggMD's platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Delaware, Florida, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Florida. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

November 07, 2023 03:47 PM Eastern Standard Time

Futura Medical continues global expansion with Latin America announcement

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after the pharmaceutical company announced another milestone in its global expansion efforts. Barder shares the news that the Futura has reached an agreement to expand its presence in Latin America. Initially, Futura Medical had been working with key markets in Mexico and Brazil, and their agreement with local partner M8 Pharmaceuticals confirmed their interest in expanding to the rest of Latin America. The deal follows others in markets around the world. Barder mentions that the company has received regulatory approval in Mexico and is preparing for its launch there, and they anticipate several more launches in the coming months. The company remains on track to execute up to 10 launches between now and the end of April. He acknowledges the frustration among shareholders due to the declining share price in recent months. He attributed this decline, in part, to macroeconomic factors and interest rate uncertainty. While the company is actively exploring ways to address this issue, Barder emphasises that the primary focus remains on product commercialisation and expansion. Despite the share price challenges, Barder says that Futura Medical maintains a robust balance sheet and is fully funded to support its ongoing growth initiatives. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 07, 2023 11:53 AM Eastern Standard Time

Video

1 ... 53 54 55 56 57 ... 280

Back